IMBM’s main purposes


IMBM is a scientific research institute focusing on biomathematical research of cellular, immunological and cancer growth processes, investigation of optimization methods for therapy of cancer, pathogenic diseases, and vaccination programs.

Responding to urgent needs

Research made by the founders of IMBM provides new ways of defining better treatment for cancer and infectious diseases. Cancer is an increasingly prevalent disease. Infectious diseases, such as HIV, are still waiting for solutions from modern medicine. Current disciplines follow the long and inefficient route of trial and error for defining therapeutic protocols and vaccination strategies. Thus, despite better prognosis for these diseases, we are still facing bewildering statistics, which are especially frustrating bearing in mind the tremendous medical, scientific and financial efforts made so far.

Searching for a new approach, bringing new hope

Cancer chemotherapy is an intricate problem, and no intuitive ways exist to evaluate how small changes in the treatment protocols will affect prognosis. IMBM applies the most advanced analytical methods, making a symbiosis of biology, medicine and mathematics, for optimizing therapeutic protocols in cancer and infectious diseases, optimizing medical intervention in the bone marrow and optimizing vaccination strategies.


Joining forces, creating the best team

The unique independent nature of IMBM is the result of a desire and plan to encourage scientists, clinicians, pharmacists and industry leaders to contribute to this important endeavor, and join forces in this exciting mission. The institute will include a core of scientists dedicated to its activities, and will enjoy the creativity and dynamics of scientists who will participate in the research for specific projects and during their sabbatical and post-doctorate periods. The founder of IMBM, Prof. Zvia Agur, has also founded the Israeli Society of Theoretical and Mathematical Biology, has been its president (1996-2001) and is active in the Board of Directors of the European Society of Mathematical and Theoretical Biology. Her original and innovative research work has received prestigious awards, and is recognized by the academic community worldwide. Scientists from various fields have already been committed to activity in the framework of IMBM, either as full-time members or as participants in various programs and projects. The support of the deeply involved Trustees is essential for the Institute’s success. Among them are members of the U.S.A Academy of Science, the Israeli Academy of Science, chief editors of most celebrated biomathematical journals, top scientists at world leading medical centers and computer industries and more.


Applying advanced research

Medical biomathematics is a new science, which by adapting theoretical mathematical models is making remarkable inroads into some of the most intractable areas of immunology and cancer research. IMBM’s work is not about the discovery or synthesis of new wonder drugs, but a radical departure from the established norms of molecular biology. It rests on the concept supported by recent research, that by mathematically investigating the major dynamics in the body of a patient undergoing medical intervention it is possible to rationalize optimal treatment strategies. To date, the results from this approach have been very favorable.


Exciting innovative projects

IMBM’s projects focus on the most concrete and practical needs of modern medicine. Among these is the mathematical study of stem cells and cancer stem cells in particular, the optimization of cancer immunotherapy, prediction of hematopoietic diseases as a result of medical interventions, etc.


Creating concrete solutions

IMBM was established with the defined mission of directing its innovative methods and tools for the benefit and free use of the scientific and medical community.

Student Supervision

Throughout its existence as a non-profit research organization, IMBM founder Professor Zvia Agur sought to enhance the field of Biomathematics by supervising MScs, MD and PhD students in collaboration with academic supervisors in the aim of guiding them in becoming independent researchers in this unique area. Among the students whose graduate studies were carried out in IMBM are the following post-doctoral, Ph.D. and M.Sc. students.

2012-2014 Mirit Kagarlizki Assessing Cancer Treatment via Biomathematical Modeling and Nonlinear Mixed Effects Statistical Models (M.Sc) (with Prof D Steinberg, Tel-Aviv University, Department of Statistics and Operations Research)
2005-2007 Dr. Natalie Kalev-Kronik (Post doctorate) Modellin GlioBlastoma Multiforme immunotherapy.  
2005 – 2006 Moran Elishmereni Role of mast cells in lung cancer: pro-tumorigenic or anti-tumorigenic? (PhD) (with Prof Levy-Schaffer. Hebrew University of Jerusalem)
2004-2006 Antonio Cappuccio (M.Sc) Cancer Immunotherapy by IL-21.  
2004 – 2006 Benjamin Ribba Angiogenesis modelling (M.Sc)(PhD) (with Lion University)
2003 – 2006 Shiri Alon Optimal Control of a Developing Tissue (M.Sc) (with I Meilijson, Tel-Aviv University, Department of Statistics and Operations Research).
2001-2002 Dr. Philippo Casteglione (Post doctorate) The effect of drug schedule on patients hypersensitivity  
2001-2002 Dr. Peteris Daugilis (Post doctorate) Bifurcation analysis in angiogenesis models